Alpha-1 MP

Phase 3

Alpha-1 MP is one of 2 therapeutic programs targeting Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyEnrolling by invitation

Pulmonary Emphysema in Alpha-1 PI DeficiencyActive, not recruiting

Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyPhase 3

Enrolling by invitation

Pulmonary Emphysema in Alpha-1 PI DeficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

#DrugCompanyPhaseTrials

Alpha-1 MP

Grifols Therapeutics LLC

Phase 3

1 2

Alpha-1 HC

Grifols Therapeutics LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Pulmonary Emphysema in Alpha-1 PI Deficiency

NCT01983241

Clinical

Trials by Indication[1]

Pulmonary Emphysema in Alpha-1 PI Deficiency1 trial

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency

Active, not recruiting· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT01983241·345 enrolled

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency1 trial

An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency

Enrolling by invitation· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT02796937·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Alpha-1 MP. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Alpha-1 MP. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Grifols Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Grifols Therapeutics LLC

Alpha-1 MP

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pulmonary Emphysema in Alpha-1 PI Deficiency1 trial

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency1 trial

References

Drug Info

Quick Facts

Related News